Marching right along with October 2014 as GLOBAL NPD Awareness month event, Day 22 day provides us with an opportunity to share research news from the laboratory of Dr. Andrew Munkacsi, who recently completed his Peter G. Pentchev research fellowship.

Trained at Columbia University Medical Center and the University of Minnesota, Dr. Munkacsi is a translational research scientist using high-throughput genomic, lipidomic, and metabolomic approaches to investigate human disease, human nutrition, molecular evolution, and functional biodiversity. His current laboratory at the Victoria University of Wellington opened in July of 2012. Dr. Munkasci’s latest update is of key importance as his work ties to the recently announced NIH Clinical trial for NPC Adults to study the safety and tolerability of vorinostat.

Project Title:

“Defining the molecular basis of HDAC inhibitors to treat murine, feline, and human models of NPC”

The National Niemann-Pick Disease Foundation (NNPDF) does not engage in the practice of medicine. It is not a medical authority nor does it claim to have medical knowledge. This site is an educational service of the National Niemann-Pick Disease Foundation and is not meant to provide diagnostic or treatment advice. Information contained or suggested on this Web site does not constitute medical advice. For all information related to care, medication or treatment, the NNPDF recommends consulting a physician to determine if information presented is applicable. Please review these additional cautions about medical information provided on the Internet.

This Web site is a service of the National Niemann-Pick Disease Foundation's Family Services Program, made possible by the financial support of our member families and other generous donors and grantors. This site receives no government funding, nor does it host or receive funding from advertising or from the display of commercial content.